🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-524199-40-00
Completed Phase II

A PET-MRI study of serotoninergic brainstem pathway in patients with Dravet Syndrome - DRAPETONINE

2025-524199-40-00 · tracked via the Priya Life Science EU tracker
Sponsor
Hospices Civils De Lyon
Sponsor type
Hospital/Clinic/Other health care facility
Therapeutic area
Nervous System Diseases
Decision date
06/02/2026
Enrollment target
30
Sites
France

Condition studied

neurology

Investigational medicinal product(s)

[18F]-MPPF

Eligibility

Age group
18-64 years
Sex
Female, Male

Primary endpoint

Comparison of the brainstem BPND of [18F]-MPPF across patients groups (DS and focal epilepsy)

Endpoint detail

Comparison of the brainstem BPND of [18F]-MPPF of each patients group (DS and focal epilepsy) with the one of healthy subjects, Comparison of the cortical BPND of [18F]-MPPF across patients groups (DS and focal epilepsy) and with the one of healthy subjects, aluating the relation between [18F]-MPPF PET brainstem regional distribution of 5HT1A receptors and inter-ictal respiratory function in patients with DS, Comparing brainstem regional volumes on MRI of patients with DS with the one of patients with drug-resistant focal epilepsy, Comparing brainstem regional volumes on MRI of each patients group (DS and focal epilepsy) with the one of healthy subjects, Evaluating the relation between the brainstem regional volumes on MRI and inter-ictal respiratory function in patients with DS

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-524199-40-00 on CTIS ↗ ← All trials in the EU